While the findings are positive overall, survival increases since the mid-1990s are especially notable for more fatal cancers ...
More than 70% of people diagnosed with cancer in the United States now survive for five years or more, a milestone experts ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell death—to survive treatment. Instead of dying, these “persister cells” ...
Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved ...
Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...
Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
Three years after launching from the lab of University of California, San Francisco chemist Jim Wells, the start-up EpiBiologics has raised $109 million in series B funding to propel its ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback